2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - 243-245
Treatment Considerations, Drug Development, Non-Biological Therapies, Pharmacology, Biological Processes, Hematopoiesis, Immune Mechanism, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Research, Fundamental Science, Translational Research
PAPER

859 Fetal hemoglobin gene therapy selectively corrects HbS polymerization but not hbc-driven pathology in HbSC disease

Tahereh Sara Setayesh, PhD, Anifat Tijani, MS2, Harsimran Kaur, MD3, Shristi Khanal, MS4, Zhenqi Zhu, PhD5, Katie Seu, PhD6, Zachery Oestreicher, PhD7, Mengna Chi, PhD8, Thouwa Samake, MS9, Ellie Savidge, n/a10, Jennifer Korpik11, Christine Schulte12, Anna Mullikin13, Abisha Crystal Christopher, PhD14, Clinton Joiner, MD15, Punam Malik, MD16
1 Division of Experimental Hematology and Cancer Biology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
2 Division of Experimental Hematology and Cancer Biology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
3 Division of Experimental Hematology and Cancer Biology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
4 Division of Experimental Hematology and Cancer Biology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
5 Division of Experimental Hematology and Cancer Biology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
6 Division of Experimental Hematology and Cancer Biology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
7 Electron Microscopy Center, University of South Carolina, Columbia, SC, United States, Columbia, South Carolina, United States
8 Division of Experimental Hematology and Cancer Biology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
9 Division of Experimental Hematology and Cancer Biology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
10 Erythrocyte Diagnostic Laboratory, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States, Cincinnati, Ohio, United States
11 Erythrocyte Diagnostic Laboratory, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States, Cincinnati, Ohio, United States
12 Cardiovascular Imaging Research Laboratory, Heart Institute, Cincinnati Children’s Hospital, Cincinnati, Ohio, United States
13 Cardiovascular Imaging Research Laboratory, Heart Institute, Cincinnati Children’s Hospital, Cincinnati, Ohio, United States
14 Division of Experimental Hematology and Cancer Biology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
15 Department of Pediatrics, Division of Hematology/Oncology/Bone Marrow Transplant, Aflac Cancer and Blood Disorders Center and Emory University School of Medicine, Atlanta, Georgia, United States
16 Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States, Division of Experimental Hematology and Cancer Biology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Background: Current genetic therapies for sickle cell disease (SCD) were developed for sickle cell anemia (SCA) to primarily prevent HbS polymerization by increasing fetal hemoglobin (HbF) or other anti-sickling globins. Hemoglobin SC disease (HbSC), however, reflects three interacting abnormalities: HbS polymerization, HbC-driven red blood cell (RBC) dehydration and oxidative HbC denaturation with membrane injury. We have shown correction of SCA in patients with lentiviral HbF delivery (Grimley et al, Nat. Med 2025). Herein, we tested correction of HbSC disease with this approach, compared to HbSS and HbCC disease in humanized mice.

Methods: Hematopoietic stem/progenitor cells (HSPC) from HbSC mice (Setayesh et al, Blood 2025) were transduced with γ-globin (GbG) or the modified g-globinG16D (GbGM) lentivectors and transplanted into irradiated HbSC recipients; mock-transduced HSPC served as controls.  Parallel gene-transfer studies were performed in HbSS and HbCC mice using the same approach to compare the effects of HbF in HbSS disease and to isolate HbC-dependent abnormalities from HbS polymerization. Mice were followed for 12 months. Beginning 9 months after transplant, subsets of HbSC mice received either an antioxidant, quercetin, or vehicle for 3 months. HbF expression, vector copy number (VCN), hematologic indices, oxygen-gradient ektacytometry (oxyscan), osmotic-gradient ektacytometry (osmoscan), shear-stress ektacytometry (SSE), KCC cotransporter activity, reactive oxygen species and oxidized hemoglobin, RBC survival, spleen volume, and whole-blood viscosity were assessed.

Results: HbSC GbG/GbGM group of mice (combined as GbG/m) maintained stable peripheral-blood VCN (2.7–2.9 copies/cell) and expressed 12–17% HbF, showing robust gene transfer but modest HbF expression. Oxyscan performed to measure sickling kinetics revealed that even modest HbF levels significantly lowered the point-of-sickling (PoS; reflecting pO2 at which sickling initiates) to 16.4 in GbG/m vs. 20.0 in mock, P=0.02, and increased elongation index minimum (EImin; reflecting RBC deformability under severe hypoxia) to 0.40 in GbG/m vs. 0.33 in mock, P=0.002. Several mice with HbF≥5% showed near-complete abrogation of hypoxia-induced sickling. However, the elongation index maximum (EImax; reflecting RBC deformability under normoxia) did not improve (0.451 in GbG/m vs. 0.448 in mock, P=0.7). We confirmed this with SSE, which also showed no improvement of EImax with HbF. EImax or RBC deformability in normoxic conditions is reduced if RBCs are dehydrated/dense or if their membranes have sustained damage.

In addition, increased HbF did not reduce reticulocytosis/RBC turnover and resulted in minimal increases in hemoglobin. In contrast, HbSS mice treated under the same conditions generated three times more HbF/vector copy and showed a significant increase in hemoglobin and reduced reticulocytosis; oxyscan showed reduced PoS, increased EImin, and EImax improved to near normal levels. At similarly high HbF levels (≥24% HbF), HbSC RBCs showed complete abrogation of sickling without any change in EImax, suggesting that RBC dehydration and oxidative membrane damage are not improved in even with high HbF.

Osmoscan confirmed that HbC-associated dehydration persisted, and urea-stimulated K-Cl cotransport and associated water loss were unchanged. Oxidative denaturation of hemoglobin, measured by ferryl hemoglobin and Heinz-body burden, were also unchanged. Notably, HbF increased oxidative stress in HbSC-RBCs in a dose-dependent manner (P<0.05). The same results were confirmed in HbCC mice transplanted with GbG-transduced HSPCs, where dehydration and oxidative damage persisted, confirming that these residual abnormalities were HbC-dependent.

Antioxidant treatment of mock and GbG/m group of HbSC mice with quercetin reduced Heinz bodies, improved EImax, both by oxyscan and SSE, prolonged RBC survival, reduced reticulocytosis and splenomegaly, and lowered whole-blood viscosity; however, dehydration remained uncorrected.

Conclusions: Unlike HbSS disease, modest HbF levels in HbSC disease nearly abolished sickling but did not change hemoglobin or RBC turnover or correct HbC-driven dehydration and oxidative injury. Quercetin complemented HbF gene therapy by improving RBC deformability, RBC survival, and reducing blood viscosity, but not dehydration. Effective HbSC correction will likely require targeting both HbS polymerization together with HbC-driven pathologies.

Tahereh Sara Setayesh, PhD: No relevant conflicts of interest to declare.